Sarepta Therapeutics Inc (NASDAQ:SRPT) is down 23.2% to trade at $77.86 at last check, and earlier hit a 52-week low of $75.06. The security is pacing for its worst single-day percentage loss since October 2023 after the gene-editing company revealed a 16-year-old boy died from acute liver failure after receiving its gene therapy for a rare muscular dystrophy. Year to date, the equity is down 37.5%. Beam Therapeutics Inc (NASDAQ:BEAM) is down 6.8% to trade at $22.85 at last glance, brushing off a price-targ ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

On Tuesday, Sarepta Therapeutics, Inc. SRPT stock is sliding. The company shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.The company reported a patient death following treatment with Elevidys, having suffered acute liver failure.Acute liver injury is a known possible side effect of Elevidys and other AAV-mediated gene therapies and is highlighted in the prescribing information.Also Read: Solid Biosciences Outpaces ...

I've been writing for Seeking Alpha since 2017 with a focus on healthcare and technology investments. With a background as a Registered Nurse, I analyze biotech stocks by evaluating clinical data, treatment guidelines, and market dynamics. My MBA provided a foundation of financial theory, allowing me to expand into technology investments, where I focus on identifying key valuation drivers and using DCF modeling for scenario-based forecasts. My thinking is influenced by books such as "Superforecasting" and " ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number : 001-14895 Sarepta Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other jurisdi ...

Sarepta Therapeutics, Inc. (SRPT) reported fourth-quarter 2024 earnings per share (EPS) of $1.50, which missed the Zacks Consensus Estimate of $1.87. However, the reported figure was significantly higher than the year-ago period’s 47 cents due to higher product sales.The loss included depreciation and amortization costs and stock-based compensation expenses. The adjusted EPS in the quarter was $1.90 compared with 82 cents in the year-ago period.Sarepta recorded total revenues of $658.4 million, up 66% year ...

Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call February 27, 2025 08:39 AM ET Company Participants Mary Jenkins - Senior Manager of Investor RelationsDouglas Ingram - President & CEODallan Murray - EVP & Chief Customer OfficerLouise Rodino-Klapac - EVP, Chief Scientific Officer & Head Of R&DIan Estepan - EVP & CFOTazeen Ahmad - MD - US Equity ResearchGena Wang - MD - Biotech Equity ResearchKevin Meli - Equity Research AssociateAndrew Tsai - SVPKostas Biliouris - Director - Equity ResearchJoseph Schwartz - ...

Patients can't wait for the next breakthrough in medical research. So neither will we. Fourth Quarter and Full Year 2024 Financial Results Wednesday, February 26, 2025 MELANIE Living with limb-girdle muscular dystrophy ©SAREPTA THERAPEUTICS, INC. 2025. ALL RIGHTS RESERVED. 1 Forward Looking Statements In order to provide Sarepta's investors with an understanding of its current results and future prospects, forward-looking statements will be made during this conference call. Any statements made by Sarepta th ...

Core Viewpoint - Sarepta Therapeutics reported quarterly earnings of $1.50 per share, missing the Zacks Consensus Estimate of $1.87 per share, representing an earnings surprise of -19.79% [1] - The company posted revenues of $658.41 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 2.83% and showing a significant increase from $396.78 million year-over-year [2] Financial Performance - Earnings per share (EPS) for the current quarter was $1.50, compared to $0.47 per share a year ago [1] - The company has surpassed consensus EPS estimates three times over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is $1.73, with expected revenues of $656.12 million, and for the current fiscal year, the EPS estimate is $10.94 on revenues of $3.03 billion [7] Market Performance - Sarepta Therapeutics shares have declined approximately 12% since the beginning of the year, while the S&P 500 has gained 1.3% [3] - The company's Zacks Rank is currently 2 (Buy), indicating expectations of outperforming the market in the near future [6] Industry Outlook - The Medical - Biomedical and Genetics industry is currently in the top 24% of over 250 Zacks industries, suggesting a favorable outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Performance - Preliminary total net product revenue of $638.2 million for Q4 2024 and $1.79 billion for full-year 2024, exceeding full-year guidance by over $100 million[4] - Total product revenue grew by 75% year-over-year in Q4 2024 and 56% over 2023 for the full year[3] - ELEVIDYS net product revenue reached $384.2 million for Q4 2024 and $820.8 million for full-year 2024, exceeding guidance by over $60 million[4] - RNA-based PMO net product revenue totaled $254.0 million for Q4 2024 and $967.2 million for full-year 2024[4] - Year-end 2024 cash, cash equivalents, restricted cash, and investments balance was approximately $1.5 billion[4] - The company reiterates 2025 full-year total net product revenue guidance of $2.9 to $3.1 billion[4] Product Information - ELEVIDYS is a gene transfer therapy for Duchenne muscular dystrophy, addressing the underlying genetic cause through micro-dystrophin production[5][6] - The company has over 40 programs in various stages of development, focusing on precision genetic medicine for rare diseases[18] Regulatory and Safety Considerations - Continued approval for ELEVIDYS in non-ambulatory patients may depend on verification of clinical benefit in confirmatory trials[7] - The company emphasizes the importance of monitoring for adverse reactions following ELEVIDYS administration, including liver injury and myocarditis[11][15]